Shanghai Runshi Pharmaceutical Technology Co., Ltd

Quick facts

Phase 3 pipeline

• Paclitaxel or docetaxel or irinotecan · Oncology
  These taxane and camptothecin chemotherapy agents stabilize microtubules or inhibit topoisomerase I to disrupt cell division and induce apoptosis in cancer cells.
• simmitinib · Other

Phase 2 pipeline

• Investigator's Choice Treatment
• simmitinib plus irinotecan liposome
• SYHA1813

Phase 1 pipeline

• Simmitinib tablets
• SYHA1815

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Shanghai Runshi Pharmaceutical Technology Co., Ltd portfolio CI brief
• Shanghai Runshi Pharmaceutical Technology Co., Ltd pipeline updates RSS